Meredith Cook Sells 400 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total transaction of $23,816.00.
• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Stock Performance

ANIP opened at $62.49 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The firm’s fifty day simple moving average is $58.40 and its two-hundred day simple moving average is $58.09.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday. They set a “buy” rating and a $80.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.75.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Pacer Advisors Inc. lifted its holdings in ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after purchasing an additional 565,910 shares in the last quarter. Millennium Management LLC lifted its holdings in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. abrdn plc purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at $13,155,000. Finally, Bank of Montreal Can purchased a new position in ANI Pharmaceuticals during the third quarter valued at $13,043,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.